Medical Care
Global Value-added Medicines (VAM) Market Research Report 2025
- Mar 11, 25
- ID: 18730
- Pages: 90
- Figures: 88
- Views: 15
The global market for Value-added Medicines (VAM) was valued at US$ 721 million in the year 2024 and is projected to reach a revised size of US$ 1450 million by 2031, growing at a CAGR of 11.3% during the forecast period.
Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.
North American market for Value-added Medicines (VAM) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Value-added Medicines (VAM) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Value-added Medicines (VAM) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Value-added Medicines (VAM) include Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Value-added Medicines (VAM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Value-added Medicines (VAM).
The Value-added Medicines (VAM) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Value-added Medicines (VAM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Value-added Medicines (VAM) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zentiva Group
MS Pharma
Towa International
CNX Therapeutics
ROVI
Elpen
Sandoz AG
Colonis
Adamed
Hyloris Pharmaceuticals SA
TIEFENBACHER GROUP
Segment by Type
Chronic Disease Treatment Drugs
Infectious Disease Treatment Drugs
Tumor Treatment Drugs
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Value-added Medicines (VAM) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.
North American market for Value-added Medicines (VAM) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Value-added Medicines (VAM) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Value-added Medicines (VAM) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Value-added Medicines (VAM) include Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Value-added Medicines (VAM), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Value-added Medicines (VAM).
The Value-added Medicines (VAM) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Value-added Medicines (VAM) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Value-added Medicines (VAM) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zentiva Group
MS Pharma
Towa International
CNX Therapeutics
ROVI
Elpen
Sandoz AG
Colonis
Adamed
Hyloris Pharmaceuticals SA
TIEFENBACHER GROUP
Segment by Type
Chronic Disease Treatment Drugs
Infectious Disease Treatment Drugs
Tumor Treatment Drugs
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Value-added Medicines (VAM) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Market Perspective (2020-2031)
2.2 Global Value-added Medicines (VAM) Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Value-added Medicines (VAM) Historic Market Size by Region (2020-2025)
2.2.3 Value-added Medicines (VAM) Forecasted Market Size by Region (2026-2031)
2.3 Value-added Medicines (VAM) Market Dynamics
2.3.1 Value-added Medicines (VAM) Industry Trends
2.3.2 Value-added Medicines (VAM) Market Drivers
2.3.3 Value-added Medicines (VAM) Market Challenges
2.3.4 Value-added Medicines (VAM) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Players by Revenue (2020-2025)
3.1.2 Global Value-added Medicines (VAM) Revenue Market Share by Players (2020-2025)
3.2 Global Value-added Medicines (VAM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Revenue
3.4 Global Value-added Medicines (VAM) Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Revenue in 2024
3.5 Global Key Players of Value-added Medicines (VAM) Head office and Area Served
3.6 Global Key Players of Value-added Medicines (VAM), Product and Application
3.7 Global Key Players of Value-added Medicines (VAM), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Historic Market Size by Type (2020-2025)
4.2 Global Value-added Medicines (VAM) Forecasted Market Size by Type (2026-2031)
5 Value-added Medicines (VAM) Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Historic Market Size by Application (2020-2025)
5.2 Global Value-added Medicines (VAM) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Value-added Medicines (VAM) Market Size (2020-2031)
6.2 North America Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Value-added Medicines (VAM) Market Size by Country (2020-2025)
6.4 North America Value-added Medicines (VAM) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Market Size (2020-2031)
7.2 Europe Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Value-added Medicines (VAM) Market Size by Country (2020-2025)
7.4 Europe Value-added Medicines (VAM) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Market Size (2020-2031)
8.2 Asia-Pacific Value-added Medicines (VAM) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2020-2025)
8.4 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Market Size (2020-2031)
9.2 Latin America Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Value-added Medicines (VAM) Market Size by Country (2020-2025)
9.4 Latin America Value-added Medicines (VAM) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Market Size (2020-2031)
10.2 Middle East & Africa Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2020-2025)
10.4 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Zentiva Group
11.1.1 Zentiva Group Company Details
11.1.2 Zentiva Group Business Overview
11.1.3 Zentiva Group Value-added Medicines (VAM) Introduction
11.1.4 Zentiva Group Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.1.5 Zentiva Group Recent Development
11.2 MS Pharma
11.2.1 MS Pharma Company Details
11.2.2 MS Pharma Business Overview
11.2.3 MS Pharma Value-added Medicines (VAM) Introduction
11.2.4 MS Pharma Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.2.5 MS Pharma Recent Development
11.3 Towa International
11.3.1 Towa International Company Details
11.3.2 Towa International Business Overview
11.3.3 Towa International Value-added Medicines (VAM) Introduction
11.3.4 Towa International Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.3.5 Towa International Recent Development
11.4 CNX Therapeutics
11.4.1 CNX Therapeutics Company Details
11.4.2 CNX Therapeutics Business Overview
11.4.3 CNX Therapeutics Value-added Medicines (VAM) Introduction
11.4.4 CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.4.5 CNX Therapeutics Recent Development
11.5 ROVI
11.5.1 ROVI Company Details
11.5.2 ROVI Business Overview
11.5.3 ROVI Value-added Medicines (VAM) Introduction
11.5.4 ROVI Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.5.5 ROVI Recent Development
11.6 Elpen
11.6.1 Elpen Company Details
11.6.2 Elpen Business Overview
11.6.3 Elpen Value-added Medicines (VAM) Introduction
11.6.4 Elpen Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.6.5 Elpen Recent Development
11.7 Sandoz AG
11.7.1 Sandoz AG Company Details
11.7.2 Sandoz AG Business Overview
11.7.3 Sandoz AG Value-added Medicines (VAM) Introduction
11.7.4 Sandoz AG Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.7.5 Sandoz AG Recent Development
11.8 Colonis
11.8.1 Colonis Company Details
11.8.2 Colonis Business Overview
11.8.3 Colonis Value-added Medicines (VAM) Introduction
11.8.4 Colonis Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.8.5 Colonis Recent Development
11.9 Adamed
11.9.1 Adamed Company Details
11.9.2 Adamed Business Overview
11.9.3 Adamed Value-added Medicines (VAM) Introduction
11.9.4 Adamed Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.9.5 Adamed Recent Development
11.10 Hyloris Pharmaceuticals SA
11.10.1 Hyloris Pharmaceuticals SA Company Details
11.10.2 Hyloris Pharmaceuticals SA Business Overview
11.10.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Introduction
11.10.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.10.5 Hyloris Pharmaceuticals SA Recent Development
11.11 TIEFENBACHER GROUP
11.11.1 TIEFENBACHER GROUP Company Details
11.11.2 TIEFENBACHER GROUP Business Overview
11.11.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Introduction
11.11.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.11.5 TIEFENBACHER GROUP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Market Perspective (2020-2031)
2.2 Global Value-added Medicines (VAM) Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Value-added Medicines (VAM) Historic Market Size by Region (2020-2025)
2.2.3 Value-added Medicines (VAM) Forecasted Market Size by Region (2026-2031)
2.3 Value-added Medicines (VAM) Market Dynamics
2.3.1 Value-added Medicines (VAM) Industry Trends
2.3.2 Value-added Medicines (VAM) Market Drivers
2.3.3 Value-added Medicines (VAM) Market Challenges
2.3.4 Value-added Medicines (VAM) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Players by Revenue (2020-2025)
3.1.2 Global Value-added Medicines (VAM) Revenue Market Share by Players (2020-2025)
3.2 Global Value-added Medicines (VAM) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Revenue
3.4 Global Value-added Medicines (VAM) Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Revenue in 2024
3.5 Global Key Players of Value-added Medicines (VAM) Head office and Area Served
3.6 Global Key Players of Value-added Medicines (VAM), Product and Application
3.7 Global Key Players of Value-added Medicines (VAM), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Historic Market Size by Type (2020-2025)
4.2 Global Value-added Medicines (VAM) Forecasted Market Size by Type (2026-2031)
5 Value-added Medicines (VAM) Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Historic Market Size by Application (2020-2025)
5.2 Global Value-added Medicines (VAM) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Value-added Medicines (VAM) Market Size (2020-2031)
6.2 North America Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Value-added Medicines (VAM) Market Size by Country (2020-2025)
6.4 North America Value-added Medicines (VAM) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Market Size (2020-2031)
7.2 Europe Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Value-added Medicines (VAM) Market Size by Country (2020-2025)
7.4 Europe Value-added Medicines (VAM) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Market Size (2020-2031)
8.2 Asia-Pacific Value-added Medicines (VAM) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2020-2025)
8.4 Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Market Size (2020-2031)
9.2 Latin America Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Value-added Medicines (VAM) Market Size by Country (2020-2025)
9.4 Latin America Value-added Medicines (VAM) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Market Size (2020-2031)
10.2 Middle East & Africa Value-added Medicines (VAM) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2020-2025)
10.4 Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Zentiva Group
11.1.1 Zentiva Group Company Details
11.1.2 Zentiva Group Business Overview
11.1.3 Zentiva Group Value-added Medicines (VAM) Introduction
11.1.4 Zentiva Group Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.1.5 Zentiva Group Recent Development
11.2 MS Pharma
11.2.1 MS Pharma Company Details
11.2.2 MS Pharma Business Overview
11.2.3 MS Pharma Value-added Medicines (VAM) Introduction
11.2.4 MS Pharma Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.2.5 MS Pharma Recent Development
11.3 Towa International
11.3.1 Towa International Company Details
11.3.2 Towa International Business Overview
11.3.3 Towa International Value-added Medicines (VAM) Introduction
11.3.4 Towa International Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.3.5 Towa International Recent Development
11.4 CNX Therapeutics
11.4.1 CNX Therapeutics Company Details
11.4.2 CNX Therapeutics Business Overview
11.4.3 CNX Therapeutics Value-added Medicines (VAM) Introduction
11.4.4 CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.4.5 CNX Therapeutics Recent Development
11.5 ROVI
11.5.1 ROVI Company Details
11.5.2 ROVI Business Overview
11.5.3 ROVI Value-added Medicines (VAM) Introduction
11.5.4 ROVI Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.5.5 ROVI Recent Development
11.6 Elpen
11.6.1 Elpen Company Details
11.6.2 Elpen Business Overview
11.6.3 Elpen Value-added Medicines (VAM) Introduction
11.6.4 Elpen Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.6.5 Elpen Recent Development
11.7 Sandoz AG
11.7.1 Sandoz AG Company Details
11.7.2 Sandoz AG Business Overview
11.7.3 Sandoz AG Value-added Medicines (VAM) Introduction
11.7.4 Sandoz AG Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.7.5 Sandoz AG Recent Development
11.8 Colonis
11.8.1 Colonis Company Details
11.8.2 Colonis Business Overview
11.8.3 Colonis Value-added Medicines (VAM) Introduction
11.8.4 Colonis Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.8.5 Colonis Recent Development
11.9 Adamed
11.9.1 Adamed Company Details
11.9.2 Adamed Business Overview
11.9.3 Adamed Value-added Medicines (VAM) Introduction
11.9.4 Adamed Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.9.5 Adamed Recent Development
11.10 Hyloris Pharmaceuticals SA
11.10.1 Hyloris Pharmaceuticals SA Company Details
11.10.2 Hyloris Pharmaceuticals SA Business Overview
11.10.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Introduction
11.10.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.10.5 Hyloris Pharmaceuticals SA Recent Development
11.11 TIEFENBACHER GROUP
11.11.1 TIEFENBACHER GROUP Company Details
11.11.2 TIEFENBACHER GROUP Business Overview
11.11.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Introduction
11.11.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (2020-2025)
11.11.5 TIEFENBACHER GROUP Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Value-added Medicines (VAM) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chronic Disease Treatment Drugs
Table 3. Key Players of Infectious Disease Treatment Drugs
Table 4. Key Players of Tumor Treatment Drugs
Table 5. Key Players of Other
Table 6. Global Value-added Medicines (VAM) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Value-added Medicines (VAM) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Value-added Medicines (VAM) Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Value-added Medicines (VAM) Market Share by Region (2020-2025)
Table 10. Global Value-added Medicines (VAM) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Value-added Medicines (VAM) Market Share by Region (2026-2031)
Table 12. Value-added Medicines (VAM) Market Trends
Table 13. Value-added Medicines (VAM) Market Drivers
Table 14. Value-added Medicines (VAM) Market Challenges
Table 15. Value-added Medicines (VAM) Market Restraints
Table 16. Global Value-added Medicines (VAM) Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Value-added Medicines (VAM) Market Share by Players (2020-2025)
Table 18. Global Top Value-added Medicines (VAM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) as of 2024)
Table 19. Ranking of Global Top Value-added Medicines (VAM) Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Value-added Medicines (VAM), Headquarters and Area Served
Table 22. Global Key Players of Value-added Medicines (VAM), Product and Application
Table 23. Global Key Players of Value-added Medicines (VAM), Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Value-added Medicines (VAM) Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Value-added Medicines (VAM) Revenue Market Share by Type (2020-2025)
Table 27. Global Value-added Medicines (VAM) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Value-added Medicines (VAM) Revenue Market Share by Type (2026-2031)
Table 29. Global Value-added Medicines (VAM) Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Value-added Medicines (VAM) Revenue Market Share by Application (2020-2025)
Table 31. Global Value-added Medicines (VAM) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Value-added Medicines (VAM) Revenue Market Share by Application (2026-2031)
Table 33. North America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Value-added Medicines (VAM) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
Table 48. Zentiva Group Company Details
Table 49. Zentiva Group Business Overview
Table 50. Zentiva Group Value-added Medicines (VAM) Product
Table 51. Zentiva Group Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 52. Zentiva Group Recent Development
Table 53. MS Pharma Company Details
Table 54. MS Pharma Business Overview
Table 55. MS Pharma Value-added Medicines (VAM) Product
Table 56. MS Pharma Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 57. MS Pharma Recent Development
Table 58. Towa International Company Details
Table 59. Towa International Business Overview
Table 60. Towa International Value-added Medicines (VAM) Product
Table 61. Towa International Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 62. Towa International Recent Development
Table 63. CNX Therapeutics Company Details
Table 64. CNX Therapeutics Business Overview
Table 65. CNX Therapeutics Value-added Medicines (VAM) Product
Table 66. CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 67. CNX Therapeutics Recent Development
Table 68. ROVI Company Details
Table 69. ROVI Business Overview
Table 70. ROVI Value-added Medicines (VAM) Product
Table 71. ROVI Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 72. ROVI Recent Development
Table 73. Elpen Company Details
Table 74. Elpen Business Overview
Table 75. Elpen Value-added Medicines (VAM) Product
Table 76. Elpen Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 77. Elpen Recent Development
Table 78. Sandoz AG Company Details
Table 79. Sandoz AG Business Overview
Table 80. Sandoz AG Value-added Medicines (VAM) Product
Table 81. Sandoz AG Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 82. Sandoz AG Recent Development
Table 83. Colonis Company Details
Table 84. Colonis Business Overview
Table 85. Colonis Value-added Medicines (VAM) Product
Table 86. Colonis Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 87. Colonis Recent Development
Table 88. Adamed Company Details
Table 89. Adamed Business Overview
Table 90. Adamed Value-added Medicines (VAM) Product
Table 91. Adamed Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 92. Adamed Recent Development
Table 93. Hyloris Pharmaceuticals SA Company Details
Table 94. Hyloris Pharmaceuticals SA Business Overview
Table 95. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product
Table 96. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 97. Hyloris Pharmaceuticals SA Recent Development
Table 98. TIEFENBACHER GROUP Company Details
Table 99. TIEFENBACHER GROUP Business Overview
Table 100. TIEFENBACHER GROUP Value-added Medicines (VAM) Product
Table 101. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 102. TIEFENBACHER GROUP Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 106. Authors List of This Report
List of Figures
Figure 1. Value-added Medicines (VAM) Picture
Figure 2. Global Value-added Medicines (VAM) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Value-added Medicines (VAM) Market Share by Type: 2024 VS 2031
Figure 4. Chronic Disease Treatment Drugs Features
Figure 5. Infectious Disease Treatment Drugs Features
Figure 6. Tumor Treatment Drugs Features
Figure 7. Other Features
Figure 8. Global Value-added Medicines (VAM) Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Value-added Medicines (VAM) Market Share by Application: 2024 VS 2031
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Other Case Studies
Figure 13. Value-added Medicines (VAM) Report Years Considered
Figure 14. Global Value-added Medicines (VAM) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Value-added Medicines (VAM) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Value-added Medicines (VAM) Market Share by Region: 2024 VS 2031
Figure 17. Global Value-added Medicines (VAM) Market Share by Players in 2024
Figure 18. Global Top Value-added Medicines (VAM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Revenue in 2024
Figure 20. North America Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Value-added Medicines (VAM) Market Share by Country (2020-2031)
Figure 22. United States Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Value-added Medicines (VAM) Market Share by Country (2020-2031)
Figure 26. Germany Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Value-added Medicines (VAM) Market Share by Region (2020-2031)
Figure 34. China Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Value-added Medicines (VAM) Market Share by Country (2020-2031)
Figure 42. Mexico Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Value-added Medicines (VAM) Market Share by Country (2020-2031)
Figure 46. Turkey Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Zentiva Group Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 50. MS Pharma Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 51. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 52. CNX Therapeutics Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 53. ROVI Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 54. Elpen Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 55. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 56. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 57. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 58. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 59. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Value-added Medicines (VAM) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chronic Disease Treatment Drugs
Table 3. Key Players of Infectious Disease Treatment Drugs
Table 4. Key Players of Tumor Treatment Drugs
Table 5. Key Players of Other
Table 6. Global Value-added Medicines (VAM) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Value-added Medicines (VAM) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Value-added Medicines (VAM) Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Value-added Medicines (VAM) Market Share by Region (2020-2025)
Table 10. Global Value-added Medicines (VAM) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Value-added Medicines (VAM) Market Share by Region (2026-2031)
Table 12. Value-added Medicines (VAM) Market Trends
Table 13. Value-added Medicines (VAM) Market Drivers
Table 14. Value-added Medicines (VAM) Market Challenges
Table 15. Value-added Medicines (VAM) Market Restraints
Table 16. Global Value-added Medicines (VAM) Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Value-added Medicines (VAM) Market Share by Players (2020-2025)
Table 18. Global Top Value-added Medicines (VAM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) as of 2024)
Table 19. Ranking of Global Top Value-added Medicines (VAM) Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Value-added Medicines (VAM), Headquarters and Area Served
Table 22. Global Key Players of Value-added Medicines (VAM), Product and Application
Table 23. Global Key Players of Value-added Medicines (VAM), Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Value-added Medicines (VAM) Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Value-added Medicines (VAM) Revenue Market Share by Type (2020-2025)
Table 27. Global Value-added Medicines (VAM) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Value-added Medicines (VAM) Revenue Market Share by Type (2026-2031)
Table 29. Global Value-added Medicines (VAM) Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Value-added Medicines (VAM) Revenue Market Share by Application (2020-2025)
Table 31. Global Value-added Medicines (VAM) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Value-added Medicines (VAM) Revenue Market Share by Application (2026-2031)
Table 33. North America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Value-added Medicines (VAM) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Value-added Medicines (VAM) Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Value-added Medicines (VAM) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Value-added Medicines (VAM) Market Size by Country (2026-2031) & (US$ Million)
Table 48. Zentiva Group Company Details
Table 49. Zentiva Group Business Overview
Table 50. Zentiva Group Value-added Medicines (VAM) Product
Table 51. Zentiva Group Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 52. Zentiva Group Recent Development
Table 53. MS Pharma Company Details
Table 54. MS Pharma Business Overview
Table 55. MS Pharma Value-added Medicines (VAM) Product
Table 56. MS Pharma Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 57. MS Pharma Recent Development
Table 58. Towa International Company Details
Table 59. Towa International Business Overview
Table 60. Towa International Value-added Medicines (VAM) Product
Table 61. Towa International Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 62. Towa International Recent Development
Table 63. CNX Therapeutics Company Details
Table 64. CNX Therapeutics Business Overview
Table 65. CNX Therapeutics Value-added Medicines (VAM) Product
Table 66. CNX Therapeutics Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 67. CNX Therapeutics Recent Development
Table 68. ROVI Company Details
Table 69. ROVI Business Overview
Table 70. ROVI Value-added Medicines (VAM) Product
Table 71. ROVI Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 72. ROVI Recent Development
Table 73. Elpen Company Details
Table 74. Elpen Business Overview
Table 75. Elpen Value-added Medicines (VAM) Product
Table 76. Elpen Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 77. Elpen Recent Development
Table 78. Sandoz AG Company Details
Table 79. Sandoz AG Business Overview
Table 80. Sandoz AG Value-added Medicines (VAM) Product
Table 81. Sandoz AG Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 82. Sandoz AG Recent Development
Table 83. Colonis Company Details
Table 84. Colonis Business Overview
Table 85. Colonis Value-added Medicines (VAM) Product
Table 86. Colonis Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 87. Colonis Recent Development
Table 88. Adamed Company Details
Table 89. Adamed Business Overview
Table 90. Adamed Value-added Medicines (VAM) Product
Table 91. Adamed Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 92. Adamed Recent Development
Table 93. Hyloris Pharmaceuticals SA Company Details
Table 94. Hyloris Pharmaceuticals SA Business Overview
Table 95. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product
Table 96. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 97. Hyloris Pharmaceuticals SA Recent Development
Table 98. TIEFENBACHER GROUP Company Details
Table 99. TIEFENBACHER GROUP Business Overview
Table 100. TIEFENBACHER GROUP Value-added Medicines (VAM) Product
Table 101. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Business (2020-2025) & (US$ Million)
Table 102. TIEFENBACHER GROUP Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
Table 106. Authors List of This Report
List of Figures
Figure 1. Value-added Medicines (VAM) Picture
Figure 2. Global Value-added Medicines (VAM) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Value-added Medicines (VAM) Market Share by Type: 2024 VS 2031
Figure 4. Chronic Disease Treatment Drugs Features
Figure 5. Infectious Disease Treatment Drugs Features
Figure 6. Tumor Treatment Drugs Features
Figure 7. Other Features
Figure 8. Global Value-added Medicines (VAM) Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Value-added Medicines (VAM) Market Share by Application: 2024 VS 2031
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Other Case Studies
Figure 13. Value-added Medicines (VAM) Report Years Considered
Figure 14. Global Value-added Medicines (VAM) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Value-added Medicines (VAM) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Value-added Medicines (VAM) Market Share by Region: 2024 VS 2031
Figure 17. Global Value-added Medicines (VAM) Market Share by Players in 2024
Figure 18. Global Top Value-added Medicines (VAM) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Revenue in 2024
Figure 20. North America Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Value-added Medicines (VAM) Market Share by Country (2020-2031)
Figure 22. United States Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Value-added Medicines (VAM) Market Share by Country (2020-2031)
Figure 26. Germany Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Value-added Medicines (VAM) Market Share by Region (2020-2031)
Figure 34. China Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Value-added Medicines (VAM) Market Share by Country (2020-2031)
Figure 42. Mexico Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Value-added Medicines (VAM) Market Share by Country (2020-2031)
Figure 46. Turkey Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Value-added Medicines (VAM) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Zentiva Group Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 50. MS Pharma Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 51. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 52. CNX Therapeutics Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 53. ROVI Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 54. Elpen Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 55. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 56. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 57. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 58. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 59. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232